PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 4, agosto 2017

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Bosutinib
• Codeine, dihydrocodeine and tramadol
• Daclizumab
• Denosumab
• Direct-acting antivirals (DAAs)
• Domperidone
• Dulaglutide
• Finasteride
• Fluconazole and fosfluconazole
• Fulvestrant
• Gadolinium agents in body scans
• Gold (I) sodium thiosulfate containing patch test products
• Hydroxocobalamin
• Loperamide (high dose)
• Loxoprofen
• Mefloquine
• Natalizumab
• Nivolumab
• Pneumococcal vaccine
• Sulfasalazine
• Thalidomide, lenalidomide and pomalidomide
• Treprostinil

SAFETY OF MEDICINE
• Bendamustine off- label use
• Brimonidine gel
• Dimethyl fumarate
• Dipeptidylpeptidase-4 (DPP-4) inhibitors
• Finasteride
• Gadolinium-based contrast agents for magnetic resonance imaging (MRI)
• Hydroxyethyl starch
• Nivolumab and pembrolizumab
• Ticagrelor
• Tramadol

SIGNAL
• Desloratadine, loratadine and weight increase in children
• Ruxolitinib and peripheral neuropathy

FEATURE
• Fourteenth Meeting of the WHO Advisory Committee on Safety of Medicinal Products (ACSoMP)
• Integrating Pharmacovigilance in Seasonal Malaria Chemoprevention: the story so far